Summary
Updated Aug 30, 2026
Brian McKelligon is President and CEO, Director of Akoya Biosciences, Inc. (AKYA). 2 SEC Form 4 filings on record going back to 2024, most recently on 8 July 2025.
Recent Transactions
5Every recent SEC Form 4 transaction Brian McKelligon has reported, most recent first.
Other Insiders Active in the Same Sector
No other insider has filed at Brian McKelligon's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Jonathan M. Rothberg - $62.19M of BFLY open-market activity in the last 12 months
- Jeffrey M. Leiden - $60.94M of VRTX open-market activity in the last 12 months
- Vivek Ramaswamy - $60.40M of ROIV open-market activity in the last 12 months
- David Cordani - $60.11M of CI open-market activity in the last 12 months
- BAKER BROS. ADVISORS LP - $60.00M of KOD open-market activity in the last 12 months
- Deep Track Biotechnology Master Fund, Ltd. - $60.00M of LBRX open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Brian McKelligon?
Brian McKelligon is a corporate insider, tracked as President and CEO, Director of Akoya Biosciences, Inc. (AKYA). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Brian McKelligon last file a Form 4?
The most recent primary Form 4 on record is dated 8 July 2025, one of 2 filings going back to 2024.
Where can I see all of Brian McKelligon's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Brian McKelligon and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
